GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care
This Viewpoint discusses the optimal treatment duration of glucagon-like peptide-1 receptor agonists in people with obesity and the benefits of off-ramping, the tapering of these antiobesity medications following an initial treatment period.
Gespeichert in:
| Veröffentlicht in: | JAMA internal medicine 2024-10 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | This Viewpoint discusses the optimal treatment duration of glucagon-like peptide-1 receptor agonists in people with obesity and the benefits of off-ramping, the tapering of these antiobesity medications following an initial treatment period. |
|---|---|
| ISSN: | 2168-6106 2168-6114 2168-6114 |
| DOI: | 10.1001/jamainternmed.2024.3579 |